ProtoKinetix (PKTX) 10-Q 15 May 14 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	15-May-14
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Trading Symbol	'pktx	'
Entity Registrant Name	'ProtoKinetix, Inc.	'
Entity Central Index Key	'0001128189	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	170,362,433
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Well Known Seasoned Issuer	'No	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets	'	'
Cash	$2,530	$2,406
Accounts receivable	0	6,020
Prepaid expenses	13,586	0
Total current assets and total assets	16,116	8,426
Current Liabilities	'	'
Accounts payable	136,823	181,399
Short-term loans	108,500	34,500
Deposit on sale	25,000	0
Convertible note payable	300,000	300,000
Total current liabilities	570,323	515,899
Stockholders' Deficiency	'	'
Common stock, $0.0000053 par value; 400,000,000 common shares authorized; 138,812,433 and 134,512,433 shares issued and outstanding for September 30, 2013 and December 31, 2012 respectively	745	722
Common stock issuable 19,162,500 shares	102	0
Share subscriptions received in advance	25,000	25,000
Additional paid-in capital	24,925,087	24,690,587
Deficit accumulated during the development stage	-25,505,141	-25,223,782
Total stockholders' deficiency	-554,207	-507,473
Total liabilities and stockholders' deficiency	$16,116	$8,426

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Common Stock, Par Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	400,000,000	400,000,000
Common Stock, Shares, Issued	138,812,433	134,512,433
Common Stock, Shares, Outstanding	138,812,433	134,512,433
Common stock issuable	19,162,500	0

STATEMENT_OF_OPERATIONS

STATEMENT OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended		165 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Revenues	$0	$0	$0	$0	$2,000
Expenses	'	'	'	'	'
Licenses	0	0	0	0	3,379,756
Professional fees	5,913	6,405	11,991	19,129	3,590,454
Consulting fees	44,375	2,231	126,458	18,731	13,491,971
Research and development	18,250	0	54,750	0	2,712,341
General and administrative	23,326	27,358	70,160	92,707	1,796,631
Interest	6,000	6,000	18,000	18,000	186,162
Operating Expenses	-97,864	-41,994	-281,359	-148,567	-25,157,315
Other income	0	0	0	0	15,000
Write-off of accounts payable	0	0	0	0	8,640
Loss on debt settlement	0	0	0	0	-330,000
Total Other Income (Expense)	0	0	0	0	-306,360
Loss from continuing operations	-97,864	-41,994	-281,359	-148,567	-25,461,675
Loss from operations of the discontinued segment	0	0	0	0	-43,466
Net loss for the period	($97,864)	($41,994)	($281,359)	($148,567)	($25,505,141)
Net loss per common share (basic and diluted)	$0	$0	$0	($0.01)	'
Weighted average number of common shares outstanding (basic and diluted)	137,948,303	94,424,390	136,067,378	125,443,940	'

STATEMENTS_OF_STOCKHOLDERS_EQU

STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT) (USD $)	Common Stock [Member]	Issuable Shares [Member]	Additional Paid-In Capital [Member]	Stock Subscriptions Received in Advance (Receivable) [Member]	Deficit Accumulated During the Development Stage [Member]	Total
Beginning Balance at Dec. 31, 2012	$722	'	$24,690,587	$25,000	($25,223,782)	($507,473)
Beginning Balance (Shares) at Dec. 31, 2012	134,512,433	'	'	'	'	'
Shares issued to settle short term loan	12	'	22,988	'	'	23,000
Shares issued to settle short term loan (Shares)	2,300,000	'	'	'	'	'
Issuance of common stock for services	11	'	19,989	'	'	20,000
Issuance of common stock for services (Shares)	2,000,000	'	'	'	'	'
Common stock issuable for services	'	102	191,523	'	'	191,625
Common stock issuable for services (Shares)	'	19,162,500	'	'	'	'
Net Income (Loss)	'	'	'	'	-281,359	-281,359
Ending Balance at Sep. 30, 2013	$745	$102	$24,925,087	$25,000	($25,505,141)	($554,207)
Ending Balance (Shares) at Sep. 30, 2013	138,812,433	19,162,500	'	'	'	'

STATEMENT_OF_CASH_FLOWS

STATEMENT OF CASH FLOWS (USD $)	9 Months Ended		165 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash Flows used in Operating Activities	'	'	'
Net loss for period	($281,359)	($148,567)	($25,505,141)
Adjustments to reconcile net loss to net cash used in operating activities	'	'	'
Depreciation expense	0	0	3,388
Write-off of accounts payable	0	0	-8,640
Loss on settlement of debt	0	0	330,000
Issuance and amortization of common stock for services	8,333	0	18,735,537
Issuance and amortization of warrants for services	0	0	2,629,730
Issuance and amortization of stock options for services	0	0	222,817
Commitment to issue common stock for services	191,625	0	191,625
Changes in operating assets and liabilities	'	'	'
Accounts receivable	6,020	1,643	0
Prepaid expenses	-1,919	18,731	61,575
Accounts payable	45,424	-1,471	235,463
Net cash used in operating activities	-31,876	-129,664	-3,103,646
Cash Flows from (used in) Investing Activities	'	'	'
Purchase of computer equipment	0	0	-3,388
Deposit on sale	25,000	0	25,000
Net cash from investing activities	25,000	0	21,612
Cash Flows from Financing Activities	'	'	'
Short-term loan proceeds (repayments)	7,000	5,265	41,500
Warrants exercised	0	0	812,314
Stock options exercised	0	0	100,500
Issuance of common stock for cash	0	125,000	1,505,250
Share subscriptions received in advance	0	0	25,000
Loan proceeds	0	0	600,000
Net cash provided by financing activities	7,000	130,265	3,084,564
Net change in cash	124	601	2,530
Cash, beginning of period	2,406	512	0
Cash, end of period	2,530	5,113	2,530
Cash paid for interest	0	0	50,222
Cash paid for income taxes	0	0	0
Supplementary information - non-cash transactions:	'	'	'
Note payable converted to common stock	0	0	330,000
Common stock issued for prepaid consulting services	20,000	0	22,231
Common stock issued to settle short-term loans	23,000	0	23,000
Common stock issued to settle convertible debt	0	0	300,000
Shares issued to settle debt	0	25,000	25,000
Commitment to issue common stock for services	191,625	0	191,625
Accounts payable converted to short-term loans	$90,000	$0	$90,000

Organization_and_Significant_A

Organization and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Organization and Significant Accounting Policies [Text Block]	'
	Note 1.	Organization and Significant Accounting Policies
	Organization
	ProtoKinetix, Inc. (the "Company"), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999. The Company is a medical research company whose mission is the advancement of human health care.
	In 2003, the Company entered into an assignment of license agreement (the "Agreement") with BioKinetix, Inc., a Canada corporation. The Agreement provided the Company with an exclusive assignment of all of the rights (the "Rights") that BioKinetix possessed relating to two proprietary technologies that are being developed for the creation and commercialization of "superantibodies," an enhancement of antibody technology that makes ordinary antibodies much more lethal. In consideration, the Company's Board of Directors authorized the Company to issue 16,000,000 shares of its common stock to the shareholders of BioKinetix.
	The Company is also currently researching the benefits and feasibility of proprietary synthesized Antifreeze Glycoproteins ("AFGP"). In preliminary studies, AFGP has demonstrated an ability to protect and preserve human cells at temperatures below freezing.
	Interim Period Financial Statements
	The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2012, included in the Company’s Annual Report on Form 10-K, filed April 30, 2014, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
	Going Concern
	As shown in the financial statements, the Company has not developed a commercially viable product, has not generated any revenues to date and has incurred losses since inception, resulting in a net accumulated deficit at September 30, 2013. These factors raise substantial doubt about the Company's ability to continue as a going concern.
	The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities. Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective. Management is presently engaged in seeking additional working capital.
	The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.
	Use of Estimates
	Preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued.
	Earnings per Share and Potentially Dilutive Securities
	Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 17,300,000 (September 30, 2012: 16,530,000) outstanding warrants and debt convertible into 12,000,000 (September 30, 2012: 12,000,000) common shares was not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses. Common stock issuable is considered outstanding as of the original approval date for purposes of earnings per share computations.
	Share-Based Compensation
	The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes option-pricing model.
	The Company accounts for stock-based compensation under "Share-Based Payment," which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. The fair value of stock options is determined using the Black-Scholes option-pricing model.
	The Company accounts for stock compensation arrangements with non-employees in accordance with FASB Codification 505 – 50 “Equity-Based Payments to Non-Employees”, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes valuation model and the compensation charges are amortized over the vesting period.
	Fair Value of Financial Instruments
	Financial instruments, including cash, accounts payable, short-term loan and convertible note payable are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.
	The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:
	Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	Financial instruments measured at fair value on the balance sheet are summarized in levels of fair value hierarchy as follows:
	Assets		Level 1		Level 2		Level 3		Total
	Cash	$	2,530	$	-	$	-	$	2,530
	Recent Accounting Pronouncements
	The management of the Company has considered all recent accounting pronouncements issued and believes that the recent pronouncements will not have a material effect on the Company’s financial statements.

Discontinued_Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2013
Discontinued Operations [Text Block]	'
	Note 2.	Discontinued Operations
	In 2003, the Company signed the licensing agreement described in Note 1. This agreement changed the Company's business plan to that of a medical research company. Accordingly, the operating results related to the Company's research prior to the licensing agreement have been presented as discontinued operations in these financial statements for all periods presented.

Accounts_Receivable

Accounts Receivable	9 Months Ended
	Sep. 30, 2013
Accounts Receivable [Text Block]	'
	Note 3.	Accounts Receivable
	The accounts receivable is refundable sales tax paid on purchases.

Short_Term_Loan

Short Term Loan	9 Months Ended
	Sep. 30, 2013
Short Term Loan [Text Block]	'
	Note 4.	Short-Term Loans
	The short-term loans are unsecured, non-interest bearing and are payable on demand.

Convertible_Note_Payable

Convertible Note Payable	9 Months Ended
	Sep. 30, 2013
Convertible Note Payable [Text Block]	'
	Note 5.	Convertible Note Payable
	On July 1, 2011, the Company executed a loan agreement under which the Company issued to a corporation an 8% convertible promissory note in exchange for $300,000. The note holder has the right to demand payment of outstanding principal and interest at any time with a 30 -day grace period. The note is due and payable no later than June 30, 2016, and is convertible into shares of the Company's common stock at $0.025 per share. No beneficial conversion feature was applicable to this convertible note.

ShareBased_Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2013
Share-Based Compensation [Text Block]	'
	Note 6.	Share-Based Compensation
	The Company has 2003 and 2004 Stock Incentive Plans. Each plan provides for the issuance of incentive and non-qualified shares of the Company's stock to officers, directors, employees, and non-employees. The Board of Directors determines the terms of the shares or options to be granted, including the number of shares or options, the exercise price, and the vesting schedule, if applicable.

Stock_Options

Stock Options	9 Months Ended
	Sep. 30, 2013
Stock Options [Text Block]	'
	Note 7.	Stock Options
	There were no stock option transactions during the nine month period ended September 30, 2013.
	At September 30, 2013 and December 31, 2012, there were no stock options outstanding.

Warrants

Warrants	9 Months Ended
	Sep. 30, 2013
Warrants [Text Block]	'
	Note 8.	Warrants
	There were 2,300,000 warrants issued during the nine month period ended September 30, 2013 and 1,530,000 warrants with an exercise price of $0.36 expired unexercised.
	Warrant transactions are summarized as follows:
						Weighted
			Number of			Average Exercise
			Warrants			Price
	Balance, December 31, 2012		16,530,000		$	0.04
	Issued		2,300,000			0.01
	Expired/Cancelled		(1,530,000	)		0.15
	Balance, September 30, 2013		17,300,000		$	0.03
	Exercisable at September 30, 2013		17,300,000		$	0.03
	At September 30, 2013, the following warrants were outstanding:
	Number of Warrants		Exercise price			Expiry Date
	12,500,000		$0.03			15-Jan-14
	2,500,000		0.03			12-Jul-14
	2,300,000		0.01			1-Oct-14
	17,300,000

Stockholders_Deficiency

Stockholders Deficiency	9 Months Ended
	Sep. 30, 2013
Stockholders Deficiency [Text Block]	'
	Note 9.	Stockholders’ Deficiency
	The Company is authorized to issue 400,000,000 shares of $0.0000053 par value common stock. Each holder of common stock has the right to one vote but does not have cumulative voting rights. Shares of common stock are not subject to any redemption or sinking fund provisions, nor do they have any preemptive, subscription or conversion rights. Holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of September 30, 2013.
	On May 9, 2014, the Company changed the number of shares of common stock that it is authorized to issue from 200,000,000 to 400,000,000.
	During the nine month period ended September 30, 2013, the Company issued 2,300,000 units to settle debt. Each unit consists of one common share and one warrant to purchase the Company’s stock. The warrants have an exercise price of $0.01 and expire October 1, 2014.
	The Company is committed to issue a total of 19,162,500 shares of common stock to arm’s length and related parties for consulting, research and investor relations services provided during the nine month period ended September 30, 2013. Related party consulting fees for the nine month period ended September 30, 2013 totaled $33,750, representing the fair value of 3,375,000 shares of common stock committed to be issued to related parties.

Subsequent_Event

Subsequent Event	9 Months Ended
	Sep. 30, 2013
Subsequent Event [Text Block]	'
	Note 10.	Subsequent Events
	1	Subsequent to the nine month period ended September 30, 2013, the Company issued 33,850,000 common shares as follows:
			Issued 8,300,000 common shares in private placements to settle a portion of the short-term loan of $83,000.
			Issued 25,550,000 common shares for services with a total valuation of $255,500.
	2	The Company entered into an agreement with Intrepid Innovation Corporation (“Intrepid”) to sell the exclusive rights for the application of the AAGP molecule. The total purchase price for the exclusive rights to the application is $2,500,000 to be paid as follows:
			$25,000 cash deposit (received);
			$25,000 paid by cash on or before April 22, 2014 as a balance of the transaction deposit;
			Six monthly payments of $25,000 on or before May 22, June 22, July 22, August 22, September 22 and October 22, 2014;
			$2,300,000 paid by the issuance of 3,500,000 restricted shares of the buyer as payment of the outstanding balance. These shares can be redeemed by a cash payment at any time within the first 6 months of the effective date of this agreement.
	Once the Company has received $2,500,000 in total through payment, sale of the shares and through the redemption of the shares, any surplus shares will be returned to Intrepid. In the event that the total payment has not totaled $2,500,000, Intrepid will pay the difference to the Company no later than 13 months after the effective date of this agreement.

Summary_of_Significant_Account

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Interim Period Financial Statements [Policy Text Block]	'
	Interim Period Financial Statements
	The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2012, included in the Company’s Annual Report on Form 10-K, filed April 30, 2014, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
Going Concern [Policy Text Block]	'
	Going Concern
	As shown in the financial statements, the Company has not developed a commercially viable product, has not generated any revenues to date and has incurred losses since inception, resulting in a net accumulated deficit at September 30, 2013. These factors raise substantial doubt about the Company's ability to continue as a going concern.
	The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities. Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective. Management is presently engaged in seeking additional working capital.
	The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.
Use of Estimates [Policy Text Block]	'
	Use of Estimates
	Preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued.
Earnings per Share and Potentially Dilutive Securities [Policy Text Block]	'
	Earnings per Share and Potentially Dilutive Securities
	Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 17,300,000 (September 30, 2012: 16,530,000) outstanding warrants and debt convertible into 12,000,000 (September 30, 2012: 12,000,000) common shares was not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses. Common stock issuable is considered outstanding as of the original approval date for purposes of earnings per share computations.
Share-Based Compensation [Policy Text Block]	'
	Share-Based Compensation
	The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes option-pricing model.
	The Company accounts for stock-based compensation under "Share-Based Payment," which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. The fair value of stock options is determined using the Black-Scholes option-pricing model.
	The Company accounts for stock compensation arrangements with non-employees in accordance with FASB Codification 505 – 50 “Equity-Based Payments to Non-Employees”, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes valuation model and the compensation charges are amortized over the vesting period.
Fair Value of Financial Instruments [Policy Text Block]	'
	Fair Value of Financial Instruments
	Financial instruments, including cash, accounts payable, short-term loan and convertible note payable are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.
	The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:
	Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	Financial instruments measured at fair value on the balance sheet are summarized in levels of fair value hierarchy as follows:
	Assets		Level 1		Level 2		Level 3		Total
	Cash	$	2,530	$	-	$	-	$	2,530
Recent Accounting Pronouncements [Policy Text Block]	'
	Recent Accounting Pronouncements
	The management of the Company has considered all recent accounting pronouncements issued and believes that the recent pronouncements will not have a material effect on the Company’s financial statements.

Organization_and_Significant_A1

Organization and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Schedule of Fair Value, by Balance Sheet Grouping [Table Text Block]	'
	Assets		Level 1		Level 2		Level 3		Total
	Cash	$	2,530	$	-	$	-	$	2,530

Warrants_Tables

Warrants (Tables)	9 Months Ended
	Sep. 30, 2013
Schedule of Warrant Activity [Table Text Block]	'
					Weighted
		Number of			Average Exercise
		Warrants			Price
	Balance, December 31, 2012	16,530,000		$	0.04
	Issued	2,300,000			0.01
	Expired/Cancelled	(1,530,000	)		0.15
	Balance, September 30, 2013	17,300,000		$	0.03
	Exercisable at September 30, 2013	17,300,000		$	0.03
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	Number of Warrants	Exercise price			Expiry Date
	12,500,000	$0.03			15-Jan-14
	2,500,000	0.03			12-Jul-14
	2,300,000	0.01			1-Oct-14
	17,300,000

Organization_and_Significant_A2

Organization and Significant Accounting Policies (Narrative) (Details)	12 Months Ended	9 Months Ended
	Dec. 31, 2003	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
		Warrant [Member]	Warrant [Member]	Convertible Debt Securities [Member]	Convertible Debt Securities [Member]
Stock issued to shareholders of BioKinetix	16,000,000	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share	'	17,300,000	16,530,000	12,000,000	12,000,000

Convertible_Note_Payable_Narra

Convertible Note Payable (Narrative) (Details) (Convertible Debt [Member], USD $)	Jul. 01, 2011
Convertible Debt [Member]	'
Convertible debt interest rate	8.00%
Convertible notes payable	$300,000
Grace period	'30 days
Convertible debt conversion price	$0.03

Warrants_Narrative_Details

Warrants (Narrative) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Warrants issued during period	2,300,000
Warrants expired/unexercised	1,530,000
Class of warrants or rights expired exercise price	$0.36

Stockholders_Deficiency_Narrat

Stockholders Deficiency (Narrative) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	9-May-14	8-May-14	Dec. 31, 2012
Common Stock, Shares Authorized	400,000,000	400,000,000	200,000,000	400,000,000
Common Stock, Par or Stated Value Per Share	$0.00	'	'	$0.00
Issuance of common stock for services	$20,000	'	'	'
Units issued during period to settle debt	2,300,000	'	'	'
Equity issuance, per share amount	$0.01	'	'	'
Consulting, Research and Investor Relations [Member]	'	'	'	'
Issuance of common stock for services (Shares)	19,162,500	'	'	'
Related Party Consulting Fees [Member]	'	'	'	'
Issuance of common stock for services (Shares)	3,375,000	'	'	'
Issuance of common stock for services	$33,750	'	'	'

Subsequent_Event_Narrative_Det

Subsequent Event (Narrative) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Issuance of common stock for services	($20,000)
Consulting, Research and Investor Relations [Member]	'
Issuance of common stock for services (Shares)	19,162,500
Related Party Consulting Fees [Member]	'
Issuance of common stock for services (Shares)	3,375,000
Issuance of common stock for services	-33,750
Subsequent Event [Member]	'
Subseqent event, shares issued	33,850,000
Issuance of common stock for services (Shares)	25,550,000
Issuance of common stock for services	255,500
Proceeds from rights agreement	2,500,000
Cash deposit received	25,000
Cash to be received	25,000
Monthly payments	25,000
Restricted shares received as payment,, shares	3,500,000
Restriced shares, value	2,300,000
Subsequent Event [Member] | Short-term loan [Member] | Private Placement [Member]	'
Common shares issued	8,300,000
Common shares issued, value	$83,000

Schedule_of_Fair_Value_by_Bala

Schedule of Fair Value, by Balance Sheet Grouping (Details) (USD $)	Sep. 30, 2013
Cash	$2,530
Level 1 [Member]	'
Cash	2,530
Level 2 [Member]	'
Cash	0
Level 3 [Member]	'
Cash	$0

Schedule_of_Warrant_Activity_D

Schedule of Warrant Activity (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Warrants beginning balance	16,530,000
Weighted average exercise price beginning balance	$0.04
Warrants issued during period	2,300,000
Weighted average exercise price warrants issued	$0.01
Warrants expired/cancelled	-1,530,000
Weighted average exercise price warrants expired/cancelled	$0.15
Warrants ending balance	17,300,000
Weighed average exercise price ending balance	$0.03
Exercisable at the end of period	17,300,000
Weighted average exercise price at the end of period	$0.03

Schedule_of_Stockholders_Equit

Schedule of Stockholders' Equity Note, Warrants or Rights (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Number of Warrants	17,300,000	16,530,000
Warrants at $0.03 expiring January 15, 2014 [Member]	'	'
Number of Warrants	12,500,000	'
Warrant Exercise Price	0.03	'
Warrants at $0.03 expiring July 12, 2014 [Member]	'	'
Number of Warrants	2,500,000	'
Warrant Exercise Price	0.03	'
Warrants at $0.01 expiring October 1, 2014 [Member]	'	'
Number of Warrants	2,300,000	'
Warrant Exercise Price	0.01	'